MADRIGAL PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 3.61 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 3.61M shares, a 0.00% change year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 3.61M shares, a 0.00% change year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 3.61M shares.
- MADRIGAL PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 3.61M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month |
|---|---|---|
| 2026-06-30 | 3.61M shares 10-Q · filed 2026-07-30 | 3.61M shares 10-Q · filed 2026-07-30 |
| 2026-03-31 | 3.61M shares 10-Q · filed 2026-05-06 | |
| 2025-06-30 | 3.61M shares 10-Q · filed 2026-07-30 | 3.61M shares 10-Q · filed 2026-07-30 |
| 2025-03-31 | 3.61M shares 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |